TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30431378

Group type: EXPERIMENTAL
Intervention: Fast weight loss method (calorie restriction, salt intake, walking, sexual self-restraint)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional drug treatment (vitamin E, orlistat, pioglitazone hydrochloride, atorvastatin, lisinopril, benzodiazepines, anti-inflammatory agents)
Number of subjects: 80
Study: 27633647

Group type: EXPERIMENTAL
Intervention: Topical tacrolimus 0.1% cream
Number of subjects: 68

Group type: COMPARATOR
Intervention: Topical clobetasol propionate 0.05% cream
Number of subjects: 68
Study: 25346265

Group type: EXPERIMENTAL
Intervention: Nasal floor elevation technique (NF group)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Sinus lift technique (MS group)
Number of subjects: 14
Study: 23581533

Group type: EXPERIMENTAL
Intervention: Aceclofenac 100 mg b.i.d.
Number of subjects: 591

Group type: COMPARATOR
Intervention: Diclofenac 50 mg t.i.d.
Number of subjects: 591
Study: 21471283

Group type: EXPERIMENTAL
Intervention: Total sleep deprivation
Number of subjects: 14
Study: 19699868

Group type: EXPERIMENTAL
Intervention: Eplerenone 25 mg, titrated to 50 mg daily
Number of subjects: 6632

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6632
Study: 16243427

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15566510

Group type: EXPERIMENTAL
Intervention: IFN 6 million units (MU) monotherapy (N=30)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination therapy with ribavirin and IFN 3 MU (N=30)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combination therapy with ribavirin and IFN 6 MU (N=60)
Number of subjects: 120
Study: 11423927

Group type: EXPERIMENTAL
Intervention: Oils high in linoleic acid (LA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Oils high in gamma-linolenic acid (GLA)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oils high in oleic acid (OA)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 24 h energy intake (EI) on the test day
Number of subjects: 16
Study: 9238624

Group type: EXPERIMENTAL
Intervention: PUFA supplementation (3.4 g daily for 12 months)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 20
Study: 8473427

Group type: EXPERIMENTAL
Intervention: Ultra-short treatment protocol (buserelin administered on days 2, 3, and 4)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Long treatment protocol (buserelin administered from mid-luteal phase)
Number of subjects: 312
Study: 2963838

Group type: EXPERIMENTAL
Intervention: 30% nitrous oxide/70% oxygen
Number of subjects: 12

Group type: COMPARATOR
Intervention: 30% room air/70% oxygen (control)
Number of subjects: 12
Study: 29570536

Group type: EXPERIMENTAL
Intervention: Exercise training (Ex)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Exercise training with low-dose testosterone (ExT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Sedentary control (CONT)
Number of subjects: 26

Group type: COMPARATOR
Intervention: All groups (including CONT)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Exercise training (Ex) and Exercise training with low-dose testosterone (ExT)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Change in twist
Number of subjects: 26
Study: 26942922

Group type: EXPERIMENTAL
Intervention: Peanut-consumption group
Number of subjects: 556

Group type: COMPARATOR
Intervention: Peanut-avoidance group
Number of subjects: 556
Study: 24735110

Group type: EXPERIMENTAL
Intervention: Geriatrician-led outreach service
Number of subjects: 116

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 116
Study: 21827579

Group type: EXPERIMENTAL
Intervention: Cyst aspiration together with tetracycline sclerotherapy (Group 1)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Only cyst aspiration without tetracycline sclerotherapy (Group 2)
Number of subjects: 96
Study: 20581300

Group type: EXPERIMENTAL
Intervention: Multiagent chemotherapy for Ewing's sarcoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Wide excision for low-grade osteosarcomas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy for high-grade osteosarcoma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Postoperative chemotherapy for low-grade or periosteal sarcomas with high-grade disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RT followed by adjuvant chemotherapy for unresectable sarcomas
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Second-line therapy for relapsed or refractory disease
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participation in clinical trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiagent chemotherapy regimens for neoadjuvant and adjuvant treatment
Number of subjects: 0
Study: 17210506

Group type: EXPERIMENTAL
Intervention: Combined transcutaneous acupoint electrical stimulation (TAES) and electromagnetic millimeter wave (EMMW) therapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 47
Study: 15870545

Group type: EXPERIMENTAL
Intervention: Recombinant activated factor VII (rFVIIa) at doses of 40, 80, and 160 microg/kg
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 12444514

Group type: EXPERIMENTAL
Intervention: Intraarticular 20 mg of tenoxicam in 20 ml normal saline (Group T)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: 50 mg bupivacaine in 20 ml normal saline (0.25%) (Group B)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intraarticular 20 mg of tenoxicam and 50 mg bupivacaine (0.25%) in 20 ml normal saline (Group BT)
Number of subjects: 75
Study: 10636314

Group type: EXPERIMENTAL
Intervention: Paediatric self-inflatable bag
Number of subjects: 80

Group type: COMPARATOR
Intervention: Adult self-inflatable bag
Number of subjects: 80
Study: 7677678

Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of fetal abdominal circumference
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Symphysiofundal height measurement
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: Combination of symphysiofundal height and fetal abdominal circumference measurement
Number of subjects: 1135

Group type: COMPARATOR
Intervention: Amniotic fluid index
Number of subjects: 1135
Study: 2188449

Group type: EXPERIMENTAL
Intervention: Buffered acetylsalicylic acid (Aspalox = 325 mg ASS plus 300 mg magnesium aluminium hydroxide) daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Unbuffered acetylsalicylic acid (325 mg) daily
Number of subjects: 12
Study: 7015492

Group type: EXPERIMENTAL
Intervention: Timolol maleat eye drops
Number of subjects: 7

Group type: COMPARATOR
Intervention: 3% carbachol ophthalmic solution
Number of subjects: 7
Study: 31486369

Group type: EXPERIMENTAL
Intervention: Adjuvant chemoradiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 0
Study: 30368324

Group type: EXPERIMENTAL
Intervention: Functional stretching exercises (thrice a week for four weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study: 26968796

Group type: EXPERIMENTAL
Intervention: Arthroscopic release of IFS
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 23
Study: 24844853

Group type: EXPERIMENTAL
Intervention: New fenofibrate tablet formulation (145 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Marketed fenofibrate tablet formulation (145 mg)
Number of subjects: 15
Study: 21769566

Group type: EXPERIMENTAL
Intervention: Tryptophan (N=20)
Number of subjects: 41

Group type: COMPARATOR
Intervention: No Tryptophan (N=21)
Number of subjects: 41
Study: 18946704

Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound-guided transbronchial needle aspiration
Number of subjects: 48
Study: 17618750

Group type: EXPERIMENTAL
Intervention: Repeated courses of antenatal steroids
Number of subjects: 86

Group type: COMPARATOR
Intervention: Single course of antenatal steroids
Number of subjects: 86
Study: 14770034

Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 11253316

Group type: EXPERIMENTAL
Intervention: Cost-benefit precuing paradigm (verbal precues for 300 pitches, 75% valid, 25% invalid)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No precuing (control condition)
Number of subjects: 20
Study: 9681586

Group type: EXPERIMENTAL
Intervention: Flunitrazepam 2 mg (FNZ2N)
Number of subjects: 6
Study: 8595650

Group type: EXPERIMENTAL
Intervention: KP model (20 pharmacies)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: State model (67 pharmacies)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control model (20 pharmacies)
Number of subjects: 600
Study: 2698505

Group type: EXPERIMENTAL
Intervention: Training group (regular stand-ups initiated on days 1-2 after admission, continued for 1-2 weeks)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 71
Study: 1105240

Group type: EXPERIMENTAL
Intervention: 30 mg SAMe intravenously twice a day for 14 days
Number of subjects: 90

Group type: COMPARATOR
Intervention: SAMe
Number of subjects: 90
Study: 31780225

Group type: COMPARATOR
Intervention: 0% SBP
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 3% SBP
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 5% SBP
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 7% SBP
Number of subjects: 200
Study: 30884073

Group type: EXPERIMENTAL
Intervention: NMES with short stimulation period
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: NMES with long stimulation period
Number of subjects: 53
Study: 28068158

Group type: EXPERIMENTAL
Intervention: Patient-led follow-up program with standardized education and access to self-referral to an assigned project nurse
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current follow-up program with routine medicals
Number of subjects: 0
Study: 25173079

Group type: EXPERIMENTAL
Intervention: Self‐Administered Interview (SAI)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control condition (filler task)
Number of subjects: 85
Study: 22418764

Group type: EXPERIMENTAL
Intervention: Low concentration of heparin (LCH) 2,500 IU/ml
Number of subjects: 75

Group type: COMPARATOR
Intervention: High concentration of heparin (HCH) 5,000 IU/ml
Number of subjects: 75
Study: 21669369

Group type: EXPERIMENTAL
Intervention: Reamed intramedullary nailing
Number of subjects: 235

Group type: COMPARATOR
Intervention: Unreamed intramedullary nailing
Number of subjects: 235
Study: 19327618

Group type: EXPERIMENTAL
Intervention: AAV1/SERCA2a (intracoronary infusion, doses ranging from 1.4 x 10(11) to 3 x 10(12) DNase resistant particles per patient)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 9
Study: 16751032

Group type: EXPERIMENTAL
Intervention: Refractive correction alone
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group from a subsequent randomized trial
Number of subjects: 84
Study: 14962728

Group type: EXPERIMENTAL
Intervention: Oral contraceptives for over 3 years
Number of subjects: 267400

Group type: EXPERIMENTAL
Intervention: Progestational injections during pregnancy
Number of subjects: 267400

Group type: EXPERIMENTAL
Intervention: Tubal ligation
Number of subjects: 267400

Group type: EXPERIMENTAL
Intervention: Ever having had an induced abortion
Number of subjects: 267400
Study: 11281052

Group type: EXPERIMENTAL
Intervention: Granulocyte Colony-Stimulating Factor (rhG-CSF) 5 micrograms/kg/day subcutaneous as a supplement to antibiotherapy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Antibiotherapy alone
Number of subjects: 28
Study: 9141211

Group type: EXPERIMENTAL
Intervention: Jet-gun administration of hepatitis B vaccine (Engerix‐B)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Syringe and needle administration of hepatitis B vaccine (Engerix‐B)
Number of subjects: 97
Study: 7583725

Group type: EXPERIMENTAL
Intervention: Dimenhydrinate (Dramamine)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study: 2204773

Group type: EXPERIMENTAL
Intervention: Piracetam
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 428220

Group type: EXPERIMENTAL
Intervention: Nova-T
Number of subjects: 1521

Group type: COMPARATOR
Intervention: Copper-T-200
Number of subjects: 1521

Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 1521
Study: 31573919

Group type: EXPERIMENTAL
Intervention: Breathing-Mentor app with biofeedback
Number of subjects: 40

Group type: COMPARATOR
Intervention: Visual instruction without biofeedback
Number of subjects: 40
Study: 28249622

Group type: EXPERIMENTAL
Intervention: Danish versions of the DISABKIDS chronic-generic and diabetes-specific modules
Number of subjects: 99
Study: 28729319

Group type: EXPERIMENTAL
Intervention: Accelerated enhanced Recovery following Minimally Invasive colorectal cancer surgery (RecoverMI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TeleRecovery (early coordinated outpatient remote televideo conferencing technology)
Number of subjects: 0
Study: 24089540

Group type: EXPERIMENTAL
Intervention: Metformin monotherapy
Number of subjects: 8192

Group type: EXPERIMENTAL
Intervention: Diet alone
Number of subjects: 8192

Group type: COMPARATOR
Intervention: Insulin monotherapy
Number of subjects: 8192

Group type: COMPARATOR
Intervention: Sulfonylurea monotherapy
Number of subjects: 8192

Group type: COMPARATOR
Intervention: Metformin plus sulfonylurea
Number of subjects: 8192

Group type: COMPARATOR
Intervention: Metformin plus insulin
Number of subjects: 8192
Study: 21854644

Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Methadone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 40
Study: 19548439

Group type: EXPERIMENTAL
Intervention: Traditional Chinese medicine (TCM) combined with transcatheter arterial chemoembolization (TACE)
Number of subjects: 67

Group type: COMPARATOR
Intervention: TACE alone
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: TCM combined with TACE
Number of subjects: 67
Study: 17911369

Group type: EXPERIMENTAL
Intervention: Sleep
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Time of day
Number of subjects: 0
Study: 15488216

Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A vaccine
Number of subjects: 2022
Study: 11517852

Group type: EXPERIMENTAL
Intervention: Placentrex treatment (Inj Placentrex 2 ml by deep intramuscular injection 5 days a week for 15 injections)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional treatment (disprin gargles and betamethasone oral drops)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Placentrex treatment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 120
Study: 8674803

Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs) for 2 weeks
Number of subjects: 48
Study: 1499063

Group type: EXPERIMENTAL
Intervention: 4.1F Multipurpose catheter
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 4.1F catheters (overall)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 4.1F Pigtail catheter
Number of subjects: 50

Group type: COMPARATOR
Intervention: 6F Judkins catheters
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Larger F sizes (5F and 6F)
Number of subjects: 50
Study: 6524612

Group type: EXPERIMENTAL
Intervention: Prostaglandin-inhibitor naproxen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 31303147

Group type: EXPERIMENTAL
Intervention: D/C/F/TAF (800/150/200/10 mg)
Number of subjects: 725

Group type: COMPARATOR
Intervention: Control (darunavir/cobicistat + emtricitabine/tenofovir disoproxil fumarate)
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: D/C/F/TAF
Number of subjects: 725

Group type: COMPARATOR
Intervention: Control
Number of subjects: 725
Study: 30240941

Group type: EXPERIMENTAL
Intervention: Integrase HIV RNA single-copy assay (iSCA)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Cobas-TaqMan HIV-1 Assay v2.0
Number of subjects: 151
Study: 26756114

Group type: EXPERIMENTAL
Intervention: Exercise program (12-month duration)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Control group (monthly health newsletter)
Number of subjects: 206
Study: 24635904

Group type: EXPERIMENTAL
Intervention: Self-reported food intake during overt phases
Number of subjects: 59

Group type: COMPARATOR
Intervention: Actual food intake measured covertly
Number of subjects: 59

Group type: COMPARATOR
Intervention: Total misreporting (combined observation and reporting effects)
Number of subjects: 59
Study: 21847570

Group type: EXPERIMENTAL
Intervention: β-blocker propranolol
Number of subjects: 0
Study: 19172143

Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine (1.5 mg/kg)
Number of subjects: 28

Group type: COMPARATOR
Intervention: 0.5% levobupivacaine (1 mg/kg)
Number of subjects: 28
Study: 17714128

Group type: EXPERIMENTAL
Intervention: Physician advice, availability of a wall mirror, availability of a partner
Number of subjects: 2126
Study: 15848577

Group type: EXPERIMENTAL
Intervention: CsA, PSL, ALG, AZA (Group A)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: CsA, PSL, ALG, DSG (Group B)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Tac, PSL, ALG, DSG (Group C)
Number of subjects: 176
Study: 12199319

Group type: EXPERIMENTAL
Intervention: Vitamin A (25,000, 50,000, and 75,000 IU daily for one year)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 9539596

Group type: EXPERIMENTAL
Intervention: 5 microg of isoproterenol
Number of subjects: 80

Group type: COMPARATOR
Intervention: 12.5 microg of epinephrine
Number of subjects: 80
Study: 7597378

Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (alpha-LNA)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Linoleic acid preparation (placebo)
Number of subjects: 22
Study: 1978947

Group type: EXPERIMENTAL
Intervention: 200 micrograms budesonide daily
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: 400 micrograms budesonide daily
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 7033865

Group type: EXPERIMENTAL
Intervention: Anterior vitrectomy during CPKP
Number of subjects: 132

Group type: COMPARATOR
Intervention: No vitrectomy during CPKP
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: APKP with anterior vitrectomy
Number of subjects: 132

Group type: COMPARATOR
Intervention: CPKP without vitrectomy
Number of subjects: 132
Study: 30898339

Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 1280

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1280
Study: 28847152

Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 30

Group type: COMPARATOR
Intervention: On-pump surgery
Number of subjects: 30
Study: 24577065

Group type: EXPERIMENTAL
Intervention: Coordinated, tailored and multidisciplinary effort (CTM)
Number of subjects: 1386

Group type: COMPARATOR
Intervention: Ordinary sickness absence management (OSM)
Number of subjects: 1386
Study: 23890317

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (2 weeks)
Number of subjects: 77

Group type: COMPARATOR
Intervention: No antibiotic (control)
Number of subjects: 77

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Number of subjects: 77
Study: 21131606

Group type: EXPERIMENTAL
Intervention: Forced correction alert
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Auto-correction alert
Number of subjects: 59

Group type: COMPARATOR
Intervention: No alerts (Control)
Number of subjects: 59
Study: 19298336

Group type: EXPERIMENTAL
Intervention: RAMC group (rabeprazole 10 mg, amoxicillin 750 mg, metronidazole 250 mg, clarithromycin 200 mg)
Number of subjects: 104

Group type: COMPARATOR
Intervention: RAM group (rabeprazole 10 mg, amoxicillin 750 mg, metronidazole 250 mg)
Number of subjects: 104
Study: 17520441

Group type: EXPERIMENTAL
Intervention: Fast-dissolving lyophilized tablet (LT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Immediate release tablet (IR)
Number of subjects: 6
Study: 14998848

Group type: EXPERIMENTAL
Intervention: Elevated serum NTx levels
Number of subjects: 250
Study: 11915777

Group type: EXPERIMENTAL
Intervention: 3-day fasting with daily training activities
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 3-day fasting with enhanced physical activity
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control (no fasting)
Number of subjects: 8
Study: 9776150

Group type: EXPERIMENTAL
Intervention: Cefonicid
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 7908501

Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 3300409

Group type: EXPERIMENTAL
Intervention: Trimeprazine
Number of subjects: 143

Group type: COMPARATOR
Intervention: Diazepam combined with droperidol
Number of subjects: 143

Group type: COMPARATOR
Intervention: Trimeprazine combined with droperidol
Number of subjects: 143

Group type: COMPARATOR
Intervention: Diazepam
Number of subjects: 143
Study: 31647139

Group type: EXPERIMENTAL
Intervention: HPFM-b (high protein-fat meal using carbohydrate and fat-protein counting)
Number of subjects: 30

Group type: COMPARATOR
Intervention: SM (standard meal using carbohydrate counting)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HPM (high protein meal using carbohydrate counting)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: HPFM-a (high protein-fat meal using carbohydrate counting)
Number of subjects: 30
Study: 29232314

Group type: EXPERIMENTAL
Intervention: Fructose-Maltodextrin (FRU + MAL)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Glucose-Maltodextrin (GLU + MAL)
Number of subjects: 8
Study: 28738799

Group type: EXPERIMENTAL
Intervention: 1% permethrin shampoo
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control group (no treatment mentioned)
Number of subjects: 300
Study: 26654631

Group type: EXPERIMENTAL
Intervention: Danhong injection (DHI)
Number of subjects: 864
Study: 22819912

Group type: EXPERIMENTAL
Intervention: pegylated IFN‐α2a (180 mcg/week) plus ribavirin (1000‐1200 mg/day) and amantadine (200mg/day) for 48 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: amantadine (200mg/day) daily for at least 24 weeks (mean 96 weeks)
Number of subjects: 43
Study: 20584129

Group type: EXPERIMENTAL
Intervention: Tadalafil 5mg once daily
Number of subjects: 160
Study: 17377767

Group type: EXPERIMENTAL
Intervention: Surfactant administration (n=8)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard treatment (n=8)
Number of subjects: 16